Envisia Therapeutics launches with $25 million in financing
Envisia Therapeutics, a biotechnology company formed by Liquidia Technologies, is being launched with $25 million in Series A financing, according to a news release.
ENV515, Envisia’s lead product, is an extended-release formulation of a prostaglandin analogue with the potential to provide sustained reduction of IOP for several months after one dose, the release said.
Envisia is also using its Particle Replication in Non-Wetting Templates (PRINT) technology to create a new line of small- and large-molecule particle-based ocular therapeutics.
Investors in Envisia include Canaan Partners, New Enterprise Associates, Pappas Ventures, Morningside Technology Ventures and Wakefield Group. Funding will be devoted to advancing ENV515 and other products in development.